OKYO Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel small-molecule therapies that modulate the innate immune system. The firm focuses on targeting key pathways involved in inflammation and fibrosis, including the stimulator of interferon genes (STING) and caspase-1. By leveraging proprietary chemistry and translational biology capabilities, OKYO aims to deliver treatments for conditions with unmet medical needs, such as oral mucositis, metabolic dysfunction, and inflammatory skin diseases.
The company’s lead investigational drug, OK-101, is a first-in-class STING agonist currently in clinical trials for prevention and treatment of oral mucositis in cancer patients. Additional pipeline candidates include OK-201, a caspase-1 inhibitor in development for nonalcoholic fatty liver disease and insulin resistance, and OK-302, a preclinical program targeting atopic dermatitis. OKYO also pursues collaborations to explore complementary immuno-modulatory approaches and expand its therapeutic footprint in fibrotic and auto-inflammatory disorders.
Originally founded as Edesa Biotech, the company rebranded to OKYO Pharma in 2022 concurrent with its listing on the Nasdaq exchange. Headquartered in Cambridge, Massachusetts, OKYO maintains research and development operations in South Korea, enabling a global reach and access to diverse scientific talent. The firm’s history integrates a strong academic foundation with industry expertise to advance its small-molecule portfolio from discovery through clinical development.
OKYO Pharma is led by Chief Executive Officer Dr. Raymond Im, whose experience in immunology and translational research guides the company’s strategic direction. Supported by a leadership team with deep backgrounds in drug discovery, clinical development, and regulatory affairs, OKYO continues to build a robust pipeline aimed at delivering new treatment options for patients suffering from debilitating inflammatory and fibrotic diseases.
AI Generated. May Contain Errors.
